Policy & Regulation
Semma Therapeutics Names Bastiano Sanna, Ph.D. as CEO, President
15 May 2018 - - Cambridge, Massachusetts-based biotechnology company Semma Therapeutics, Inc. has appointed Bastiano Sanna, Ph.D. as chief executive officer and president, the company said.
Sanna will succeed Elizabeth Stoner, M.D., who has been serving as the interim CEO and will remain as an advisor to the company.
Sanna joins Semma from Magenta Therapeutics, where he served as chief operating officer. Prior to Magenta, he served in a leadership team of Novartis' cell and gene therapy unit as the global program head of stem cell transplant and early programs.
In an earlier role, he served as global head of strategic planning and portfolio management at the Novartis Institutes for BioMedical Research.
Semma Therapeutics is pioneering the curative use of stem cells in regenerative medicine by coupling its breakthrough stem cell technologies with proprietary delivery systems designed to protect cells from the immune system.
Its ongoing research is focused on combining these highly-differentiated active cells with a state-of-the-art device to provide a functional cure for patients with diabetes. Geadquartered in Cambridge, MA, the company has operations in Providence, RI.


Related Headlines